M. Renee Ward

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

Anas Younes, Yasuhiro Oki, R. Gregory Bociek et al. · The Lancet Oncology · 2011 · 195 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

A pilot pharmacokinetic study of oral azacitidine

Guillermo Garcia‐Manero, M. Stoltz, M. Renee Ward et al. · Leukemia · 2008 · 68 citations

Pharmacy, Pharmacokinetics, Pharmacology +6

Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

Michael E. Rothenberg, Michael Tagen, Jae H. Chang et al. · Clinical Drug Investigation · 2019 · 47 citations

Medicine, Pharmacokinetics, Pharmacology +8

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Anas Younes, Barbara Pro, Michelle A. Fanale et al. · Blood · 2007 · 35 citations

Medicine, Oncology, Pharmacology +12

[O2–17–03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD‐TO‐MODERATE AD

Geoffrey A. Kerchner, Gai Ayalon, Flávia Brunstein et al. · Alzheimer s & Dementia · 2017 · 12 citations

Life Sciences, Neurology, Neuroscience +17